Current Urology Reports

, Volume 8, Issue 3, pp 185–189

Testosterone replacement therapy and prostate cancer: A word of caution

  • Timothy C. Brand
  • Edith Canby-Hagino
  • Ian M. Thompson

DOI: 10.1007/s11934-007-0004-x

Cite this article as:
Brand, T.C., Canby-Hagino, E. & Thompson, I.M. Curr Urol Rep (2007) 8: 185. doi:10.1007/s11934-007-0004-x


The number of men for whom testosterone is prescribed is rapidly increasing. The aging man normally demonstrates a gradual decline in testosterone. Symptoms of hypogonadism include erectile dysfunction, diminished libido, sarcopenia, increased adiposity, osteopenia and osteoporosis, impaired cognition, and depression. There is a paucity of data regarding both efficacy and safety of testosterone replacement therapy. Testosterone levels have been shown to modulate prostate cancer risk and progression. A prospective evaluation of prostate cancer risk with testosterone replacement therapy has not been conducted. We outline concerns and recommendations for the use of testosterone replacement therapy in the aging man.

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Timothy C. Brand
    • 1
  • Edith Canby-Hagino
  • Ian M. Thompson
  1. 1.Department of UrologyUniversity of Texas Health Science Center at San AntonioSan AntonioUSA